This course has expired. You can still review the content but course credit is no longer available.
Female sexual dysfunction (FSD) is an overall umbrella disease that may affect as many as 40 million women in the U.S., with prevalence rates cited from 30% to as high as 80%. The etiology of FSD, however, is less well-defined or understood. Comprising both physiological and psychological aspects, FSD can manifest in a variety of ways. This educational activity will include discussions on the definition, prevalence, diagnosis and related guidelines for managing this disease state.
Supported through an educational grant from Valeant Pharmaceuticals International.
Upon completion of this activity, the participant should be able to:
Evolve Medical Education LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
AMA Credit Designation Statement
Evolve Medical Education LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This continuing medical education activity is supported through unrestricted educational grants from Valeant Pharmaceuticals North America LLC.
Anita H. Clayton, MD
David C. Wilson Professor and Chair
Department of Psychiatry & Neurobehavioral Sciences
Professor of Clinical Obstetrics & Gynecology
James A. Simon, MD, CCD, NCMP, IF, FACOG
Department of Ob/Gyn
George Washington University
Women’s Health & Research Consultants®
The following faculty members have the following financial relationships with commercial interests:
Anita H. Clayton, MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Forest, now Allergan; Palatin Technologies; S1 Biopharma; Sprout Pharmaceuticals, a division of Valeant. Grant/Research Support: Aspex Pharmaceuticals; Axsome; Forest Research Institute, now Allergan; Genomind; Janssen; Palatin Technologies; and Takeda Pharmaceuticals. Stock Shareholder: Euthymics and S1 Biopharma. Royalties/Copyright: Ballantine Books/Random House; Guilford Publications; Changes in Sexual Functioning Questionnaire.
Simon MD has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: AbbVie, Inc.; Allergan, Plc; AMAG Pharmaceuticals, Inc.; Amgen Inc.; Apotex, Inc.; Ascend Therapeutics; Azure Biotech, Inc.; Eisai, Inc.; JDS Therapeutics, LLC; Merck & Co., Inc; Millendo Therapeutics, Inc.; Noven Pharmaceuticals, Inc.; Novo Nordisk; Nuelle, Inc.; Perrigo Company, PLC; Radius Health, Inc.;, Regeneron Pharmaceuticals, Inc.; Roivant Sciences, Inc.; Sanofi S.A.; Sebela Pharmaceuticals, Inc.; Sermonix Pharmaceuticals, Inc.; Shionogi Inc.; Sprout Pharmaceuticals; Symbiotec Pharmalab; TherapeuticsMD; and Valeant Pharmaceuticals. Grant/Research Support: AbbVie, Inc.; Actavis, PLC; Agile Therapeutics; Bayer Healthcare LLC.; GlaxoSmithKline’ New England Research Institute, Inc.; Novo Nordisk; Palatin Technologies; Symbio Research, Inc.; and TherapeuticsMD. Patent and Trademark Holder: U.S. Patent: 4,816,257, March 28, 1989: “Method for Producing an In Vivo Environment Suitable for Human Embryo Transplant.”, U.S. Trademark: Reg. No. 3,446,895, Registered June 10, 2008: “You talk…I’ll Listen. We’ll Plan Together”. U.S. Trademark: Reg. No. 3,676,269, Registered September 1, 2009: U.S. Trademark: Reg. No. 3,760,080, Registered March 16, 2010: “Women’s Health & Research Consultants & Design”, U.S. Trademark Serial No.:86-714,153. “DR. SIMON SAYS” Registered February 2, 2016. Stock Shareholder and/or other Financial Support: Sermonix Pharmaceuticals.
Michelle Dalton, Writer and Cheryl Cavanaugh, MS, Evolve Medical Education LLC have no real or apparent conflicts of interest to report.
Rishi P. Singh, MD, Peer Reviewer, has had a financial agreement or affiliation during the past year with the following commercial interests in the form of Consultant/Advisory Board/Speaker’s Bureau: Alcon; Allergan Inc.; Carl Zeiss Meditec; Genentech, Inc; Optos; Regeneron Pharmaceuticals, Inc; and Shire Plc. Grant/Research Support: Alcon; Apellis Pharmaceuticals; Genentech, Inc; and Regeneron Pharmaceuticals, Inc.